Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.
11/14/26
Collegium Pharmaceutical (COLL)
Saturday
4:07 PM ET
ThesisCollegium Pharmaceutical: the story is balanced — Xtampza ER prescription volume trends and market share gains versus competitive abuse-deterrent opioids
value - The stock trades at attractive cash flow multiples (5.7x EV/EBITDA, 14% FCF yield) appealing to value investors seeking mispriced…
Rising rates increase debt service costs on the company's leveraged balance sheet (3.4x debt/equity)…
Watch on earnings: Weekly Xtampza ER and Belbuca prescription data from IQVIA or Symphony Health tracking market share trends, Quarterly gross-to-net revenue adjustments indicating payer rebate pressure and formulary positioning, CDC opioid prescribing data and morphine milligram equivalent (MME) trends showing overall market dynamics.
One Sentence Summary:
Collegium Pharmaceutical: the story is balanced — xtampza er prescription volume trends and market share gains versus competitive abuse-deterrent opioids.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.